Trials / Withdrawn

WithdrawnNCT00283764

Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device

Status: Withdrawn
Phase: Phase 3
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Xalatan

Timeline

First posted: 2006-01-30
Last updated: 2021-02-02

Source: ClinicalTrials.gov record NCT00283764. Inclusion in this directory is not an endorsement.